Showing 1501-1510 of 1564 results for "".
- BioTime Announces Closing of Acquisition of Asterias Biotherapeuticshttps://modernod.com/news/biotime-announces-closing-of-acquisition-of-asterias-biotherapeutics/2476362/BioTime announced the closing of its previously reported acquisition of Asterias Biotherapeutics, whereby BioTime has acquired through a merger, all of the remaining outstanding common stock of Asterias which was not previously owned by BioTime. As a result of the acquisition, Asterias became a w
- New Laser Helps Doctors Image Full Eye in 3Dhttps://modernod.com/news/new-laser-helps-doctors-image-full-eye-in-3d/2476348/Scientists have developed a laser-based technique that can produce a full 3D image of all the layers of the retina, allowing doctors to better diagnose and treat eye diseases such as cataracts, diabetic retinopathy, and cancer, according to an Octlight news release. Researchers from the Te
- Roche Acquires Spark Therapeutics in $4.8 Billion Dealhttps://modernod.com/news/roche-acquires-spark-therapeutics-in-4-3-billion-deal/2476268/Swiss pharma giant Roche acquired and Philadelphia-based gene therapy company Spark Therapeutics in an all cash transaction worth $4.8 billion, or $114.50 per share. The merger has been unanimously approved by the boards of Spark Therap
- EyeBrain Medical and IDOC Announce Partnership to Bring Neurolens to IDOC Independent Optometristshttps://modernod.com/news/eyebrain-medical-and-idoc-announce-partnership-to-bring-neurolens-to-idoc-independent-optometrists/2476270/IDOC and eyeBrain Medical announced a multiyear partnership to bring neurolens prescription lenses to all IDOC members across the United States. Neurolenses are the first and only prescription lenses that add a contoured prism to bring the eyes into alignment. Contoured prisms have been shown in
- ReNeuron Group Announces Positive Preliminary Data in US Retinitis Pigmentosa Trialhttps://modernod.com/news/reneuron-group-announces-positive-preliminary-data-in-us-retinitis-pigmentosa-trial/2476276/ReNeuron Group announced positive preliminary results in the company’s ongoing phase 1/2 clinical trial of its human retinal progenitor cells (hRPC) cell therapy candidate in retinitis pigmentosa (RP). All three subjects in the first cohort of the phase 2 part of the trial have demonstrate
- Bausch Health to Purchase Majority of Synergy Pharmaceuticals’ Assets, Including Trulancehttps://modernod.com/news/bausch-health-to-purchase-majority-of-synergy-pharmaceuticals-assets-including-trulance/2479614/Bausch Health announced a deal to purchase nearly all of the assets of bankrupt drugmaker Synergy Pharmaceuticals for about $200 million in cash, with the transaction including the constipation treatment Trulance (plecanatide), according to FirstWord. Bausch Health CEO Joseph Papa noted that the
- Criminal Case Against James Mazzo Dismissedhttps://modernod.com/news/criminal-case-against-james-mazzo-dismissed/2476151/After a legal battle that spanned a decade, the insider trading criminal case against ophthalmic executive James Mazzo has come to an end. Late Thursday at the Ronald Reagan Federal Building in Santa Ana, California, federal prosecutors asked Judge Andrew Guilford to dismiss all criminal c
- Center for Vision and Population Health at Prevent Blindness Established to Implement Strategies to Address Eye Healthhttps://modernod.com/news/center-for-vision-and-population-health-at-prevent-blindness-established-to-implement-strategies-to-address-eye-health/2476154/Healthy vision can be a key component to independence and well-being for people of all ages. However barriers such as poor access to eye care, lack of insurance coverage, and inconsistent policies for eye health can prevent early detection and treatment of eye disorders. Prevent Blindness,
- Gene Therapy Luxturna Approved in EU to Restore Vision in People With Rare Inherited Retinal Diseasehttps://modernod.com/news/gene-therapy-luxturna-approved-in-eu-to-restore-vision-in-people-with-rare-inherited-retinal-disease/2479651/Novartis announced that the European Commission (EC) approved Luxturna, a one-time gene therapy for the treatment of patients with vision loss due to a genetic mutation in both copies of the RPE65 gene and who have enough viable retinal cells. The authorization is valid in all 28 member st
- Restoring Sight: Clinical Progress Toward Australia’s Bionic Eyehttps://modernod.com/news/restoring-sight-clinical-progress-towards-australias-bionic-eye/2479658/Bionic Vision Technologies (BVT) announced medical researchers had successfully restored a sense of vision in four blind people with its bionic eye as part of a clinical trial in Melbourne. Researchers said they were “very pleased” with the progress of all four patients who have had a “sen